Bertrand Le Bourdonnec

Inhibiting Stearoyl-CoA Desaturase Ameliorates α-Synuclein Cytotoxicity

Benjamin Vincent, Daniel F. Tardiff, Jeff S. Piotrowski et al. · Cell Reports · 2018 · 130 citations · Full text

Potent, Orally Bioavailable Delta Opioid Receptor Agonists for the Treatment of Pain: Discovery of<i>N</i>,<i>N</i>-Diethyl-4-(5-hydroxyspiro[chromene-2,4′-piperidine]-4-yl)benzamide (ADL5859)

Bertrand Le Bourdonnec, Rolf T. Windh, Christopher W. Ajello et al. · Journal of Medicinal Chemistry · 2008 · 89 citations · Full text

Spirocyclic Delta Opioid Receptor Agonists for the Treatment of Pain: Discovery of<i>N</i>,<i>N</i>-Diethyl-3-hydroxy-4-(spiro[chromene-2,4′-piperidine]-4-yl) Benzamide (ADL5747)

Bertrand Le Bourdonnec, Rolf T. Windh, Lara K. Leister et al. · Journal of Medicinal Chemistry · 2009 · 83 citations · Full text

δ-Opioid Mechanisms for ADL5747 and ADL5859 Effects in Mice: Analgesia, Locomotion, and Receptor Internalization

Chihiro Nozaki, Bertrand Le Bourdonnec, David J. Reiss et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 73 citations · Full text

The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease

James B. Koprich, Susan H. Fox, Tom H. Johnston et al. · Movement Disorders · 2011 · 68 citations